1
|
Shamshiripour P, Nikoobakht M, Mansourinejad Z, Ahmadvand D, Akbarpour M. A comprehensive update to DC therapy for glioma; a systematic review and meta-analysis. Expert Rev Vaccines 2022; 21:513-531. [DOI: 10.1080/14760584.2022.2027759] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Parisa Shamshiripour
- Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
- Department of medical imaging technology and molecular imaging, Iran University of Medical Sciences, Tehran, Iran
| | - Mehdi Nikoobakht
- Department of Neurosurgery, Iran University of Medical Sciences, Tehran, Iran
| | - zahra Mansourinejad
- Department of systems biology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
| | - Davoud Ahmadvand
- Department of medical imaging technology and molecular imaging, Iran University of Medical Sciences, Tehran, Iran
| | - Mahzad Akbarpour
- Advanced Cellular Therapeutics Facility, David and Etta Jonas Center for Cellular Therapy, Hematopoietic Cellular Therapy Program, The University of Chicago Medical Center, Chicago 60637 IL, USA
- Immunology Board for Transplantation and Cell-Based Therapeutics (Immuno-TACT), Universal Science and Education Research Network (USERN), Chicago, USA
| |
Collapse
|
2
|
Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. DRUG DESIGN DEVELOPMENT AND THERAPY 2020; 14:1177-1189. [PMID: 32256049 PMCID: PMC7090185 DOI: 10.2147/dddt.s243787] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Accepted: 02/20/2020] [Indexed: 12/18/2022]
Abstract
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian population. Methods Camrelizumab was administered to patients with advanced solid tumors who had failed standard therapies. In the dose-escalation phase (n=23), camrelizumab was administered intravenously at 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks. In dose expansion (n=26), camrelizumab was given at 200 mg or 600 mg every 4 weeks. Results Two dose-limiting toxicities were observed during dose escalation: transaminase elevation and diarrhea (both grade 3). Overall, treatment-related adverse events were consistent with the expected toxicity profile of immune checkpoint inhibition, with the striking exception of the dose-related development of angiomatous skin lesions characterized as reactive cutaneous capillary endothelial proliferation. The PK profile showed a dose-progressive increase in half-life from 3 days at 1 mg/kg to 7 days at 10 mg/kg. Moreover, receptor occupancy assays showed a PD-1 occupancy of >50% in most patients out to 28 days post-dose. The objective response rate was 15.2% (95% CI 6.3–28.9). Conclusion Camrelizumab has manageable toxicity and encouraging preliminary antitumor activity in advanced solid tumors in Australia. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT02492789.
Collapse
Affiliation(s)
| | - Hui K Gan
- Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia.,Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Melbourne, Victoria, Australia.,Department of Medical Oncology, La Trobe University School of Cancer Medicine, Bundoora, Victoria, Australia
| | - Mark Voskoboynik
- Nucleus Network, Melbourne, Victoria, Australia.,Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.,Department of Medical Oncology, Monash University, Central Clinical School, Alfred Campus, Melbourne, Victoria, Australia
| | - Surein Arulananda
- Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia.,Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Melbourne, Victoria, Australia.,Department of Medical Oncology, La Trobe University School of Cancer Medicine, Bundoora, Victoria, Australia
| | - Bo Gao
- Blacktown Cancer and Haematology Centre, Blacktown Hospital, University of Sydney, Sydney, New South Wales, Australia
| | - Adnan Nagrial
- Blacktown Cancer and Haematology Centre, Blacktown Hospital, University of Sydney, Sydney, New South Wales, Australia
| | - Peter Grimison
- Department of Medical Oncology, Chris O'Brien Life House, Camperdown, New South Wales, Australia
| | - Michelle Harrison
- Department of Medical Oncology, Chris O'Brien Life House, Camperdown, New South Wales, Australia
| | - Jianjun Zou
- Jiangsu Hengrui Medicine Co. Ltd, Shanghai, People's Republic of China
| | - Lianshan Zhang
- Jiangsu Hengrui Medicine Co. Ltd, Shanghai, People's Republic of China
| | - Stacey Luo
- Jiangsu Hengrui Medicine Co. Ltd, Shanghai, People's Republic of China
| | - Michael Lahn
- Incyte Biosciences International Sarl, Geneva, Switzerland
| | | | | | - Catello Somma
- Incyte Biosciences International Sarl, Geneva, Switzerland
| | - Katherine Woods
- Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Melbourne, Victoria, Australia
| | - Andreas Behren
- Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Melbourne, Victoria, Australia.,Department of Medical Oncology, La Trobe University School of Cancer Medicine, Bundoora, Victoria, Australia
| | - Pablo Fernandez-Penas
- Department of Dermatology, The University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
| | - Michael Millward
- Linear Clinical Research, Nedlands, Western Australia, Australia
| | - Tarek Meniawy
- Linear Clinical Research, Nedlands, Western Australia, Australia
| |
Collapse
|